



Digital RESI Three Day Conference (June 8 - 10)

- **400+ Investors & Strategic Partners**
- Top-notch, insightful panels and workshops on relevant topics in early stage life science funding
- Global Innovation Challenge of cutting edge technologies
- Book **THREE DAYS** of one to one meetings
- Largest gathering of international investors and channel partners seeking early stage partnerships

Ask us your discount code to get \$100 off your Digital RESI June registration.

REGISTER NOW

The Digital RESI 3-Day Conference (June 8-10) has two great ways for you to get valuable visibility: the RESI Innovation Challenge (IC) and Featured Company Pitch Sessions (FCPS).

	<u>RESI Innovation Challenge</u>	<u>Featured Company Pitch Sessions</u>
Application and Evaluation	<u><i>Merit-Based, 30 Finalists</i></u>	<u><i>Streamlined, rolling acceptance</i></u>
Deadlines	Application deadline extends to May 11 th	Reduced price through May 11 th
Fee to Participate <i>(in addition to event registration)</i>	Free	\$500 before May 11 th \$750 after May 11 th
After the Conference	Top three companies through RESI attendees' voting receive awards	Companies have a live Q&A session with a panel of relevant investors
Dedicated Landing Page <i>(See Below Example Page)</i>	Yes	Yes

Digital RESI Innovation Challenge Landing Page Example



MOWOOT
The solution to chronic constipation

VOTE FOR US



MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a purely physical, non-drug, non-invasive solution.

MOWOOT offers a CE certified (Med Dev. class IIa), IP protected, clinically validated and award-winning technology: the first Intermittent Colonic Exo-peristalsis (ICE) device on the market handling a large unmet need for patients with Neurogenic-Bowel-Disorders (NBD), Idiopathic Chronic Constipation (ICC) and Opioid-Induced-Constipation (OIC).

The Global Market for the indication "chronic constipation" alone has an annual worth of US\$ 12.58 bn, with a healthy CAGR of 7.1%, estimated to reach US\$ 22.93 bn by 2025.

- MOWOOT Slide Deck
- MOWOOT Data Sheet One-pager
- MOWOOT Product Info

Interested in Connecting? Please contact:
Markus Wilhelms
CEO
markus@mowoot.com

Message the company or request a 1:1 meeting here.

MOWOOT is a growth stage **medical device** company targeting **intestinal transit disorders** with a purely physical, **non-drug, non-invasive** solution.

www.mowoot.com

Slow intestinal Transit & Chronic Constipation a huge unmet need:

- **High Prevalence:** 250M people in EU & USA (24% of Gen Pop / 60% of elderly / 80% of Neurol. Patients)
- **Severe Secondary Problems:** from embarrassing (incontinence) to life threatening (cancer; prolapse;...)
- **High Health Economic Burden** outlined as much as \$100B annually in EU & USA
- **Current Approaches have Side Effects & are Expensive** (laxatives, drugs, enemas or surgical solutions)

Novel non-drug, non-invasive solution:

MOWOOT
Intestinal Transit Management System:

- Purely physical stimulation of gut motility & secretion
- Clinically proven results with **only 10-20 minutes once daily** treatment
- Lightweight belt is easy to put on (over clothes)
- Patented Exo-peristalsis Technology resembles professional manual colonic massage by therapists

Market:

Beachhead Target Indication:

- **Neurogenic Bowel Disorders (NBD)**
Global Annual Market \$365M w/ CAGR 3%

Future Indications:

- **Idiopathic Chronic Constipation (ICC)**
Global Annual Market \$12.68 w/ CAGR 7.1%
- **Opioid-Induced-Constipation (OIC)**
Global Annual Market \$3.7B w/ CAGR 32%
- **Health & Wellness (OTC device)**
Global Annual Market \$64B w/ CAGR 4.4%

Executive Team:

Dr. Markus Wilhelms, CEO
PhD, Expert in Needs-driven Innovation

Dr. Immaculada Herrero, CSO
PhD, Expert in Clinical Studies

Marc Benet, CRMO
MSc, Expert in Med. Dev. QMS & Regulatory

Dr. Angel Calzada, CTO
PhD, Expert in Software Dev. & Supply Chain MGMT

Josep Molinero, CFO
MBA, MSc, STMG, Expert in Finance

Plus:

Intl. Advisory Board
Experienced Medtech Entrepreneurs

Medical KOL
In Neurogenic Bowel Dysfunction

Milestones:

- ✓ **Product:** on the market & pipeline dev.
- ✓ **Regulatory:** CE (med. Dev. Class IIa), ISO 13485 certification, PCT/IB2015/001576
- ✓ **IP:** 1 multicentric international study
- ✓ **Clinical:** 2 published pilot studies
- ✓ **Biz Dev:** 1 multicentric international study
- ✓ **Market Acceptance:** First sales & distribution partners in GER, UK, NL & DK; Device in use in 30 EU KOL centers; State-of-the-Art in "Neurogenic Bowel" SCI clinical guideline (GER); Majority of sales already reimbursed by private healthcare insurances; *Public reimbursement expected in H1 2020 (GER) & H1 2021 (UK)*

€2.6M
Raised to Date

€330K
Revenue in 2019

7
Current Head Count

Contact: Markus Wilhelms - CEO&Co-founder - markus@mowoot.com

We'd love to hear from you! For more information, contact the RESI Team at resi@lifesciencenation.com